Sage Therapeutics, Inc. (NASDAQ:SAGE) Shares Sold by Ameriprise Financial Inc.

Ameriprise Financial Inc. lowered its holdings in Sage Therapeutics, Inc. (NASDAQ:SAGE - Free Report) by 41.3% in the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 125,630 shares of the biopharmaceutical company's stock after selling 88,350 shares during the quarter. Ameriprise Financial Inc. owned 0.21% of Sage Therapeutics worth $682,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other hedge funds have also recently modified their holdings of SAGE. Picton Mahoney Asset Management boosted its stake in shares of Sage Therapeutics by 126.0% in the fourth quarter. Picton Mahoney Asset Management now owns 6,423 shares of the biopharmaceutical company's stock worth $35,000 after acquiring an additional 3,581 shares during the period. KLP Kapitalforvaltning AS bought a new position in Sage Therapeutics during the fourth quarter valued at approximately $49,000. Ieq Capital LLC bought a new position in Sage Therapeutics during the fourth quarter valued at approximately $57,000. US Bancorp DE boosted its stake in Sage Therapeutics by 22.3% during the fourth quarter. US Bancorp DE now owns 12,430 shares of the biopharmaceutical company's stock valued at $67,000 after buying an additional 2,268 shares during the last quarter. Finally, Teacher Retirement System of Texas boosted its stake in Sage Therapeutics by 21.6% during the fourth quarter. Teacher Retirement System of Texas now owns 13,768 shares of the biopharmaceutical company's stock valued at $75,000 after buying an additional 2,446 shares during the last quarter. Hedge funds and other institutional investors own 99.22% of the company's stock.

Sage Therapeutics Trading Up 3.7%

Shares of NASDAQ SAGE traded up $0.24 during trading on Thursday, reaching $6.78. 900,047 shares of the company traded hands, compared to its average volume of 1,180,711. The firm's fifty day simple moving average is $7.04 and its 200 day simple moving average is $6.77. The stock has a market cap of $424.57 million, a P/E ratio of -1.03 and a beta of 0.20. Sage Therapeutics, Inc. has a 12-month low of $4.62 and a 12-month high of $13.47.

Sage Therapeutics (NASDAQ:SAGE - Get Free Report) last released its quarterly earnings data on Tuesday, April 29th. The biopharmaceutical company reported ($1.01) earnings per share for the quarter, missing analysts' consensus estimates of ($0.99) by ($0.02). Sage Therapeutics had a negative net margin of 971.50% and a negative return on equity of 68.18%. The company had revenue of $14.06 million for the quarter, compared to analysts' expectations of $14.12 million. During the same quarter in the previous year, the business posted ($1.80) EPS. The business's quarterly revenue was up 78.0% on a year-over-year basis. As a group, research analysts expect that Sage Therapeutics, Inc. will post -3.52 EPS for the current year.

Analyst Upgrades and Downgrades

A number of equities research analysts have issued reports on SAGE shares. Needham & Company LLC restated a "hold" rating on shares of Sage Therapeutics in a research report on Friday, April 25th. Canaccord Genuity Group decreased their price objective on Sage Therapeutics from $9.00 to $8.00 and set a "hold" rating on the stock in a research report on Wednesday, February 12th. HC Wainwright reiterated a "neutral" rating and issued a $12.00 price target (down from $14.00) on shares of Sage Therapeutics in a report on Wednesday, February 12th. Scotiabank reduced their price target on Sage Therapeutics from $14.00 to $12.00 and set a "sector outperform" rating on the stock in a report on Wednesday, February 12th. Finally, Wedbush reiterated a "neutral" rating and issued a $6.00 price target on shares of Sage Therapeutics in a report on Wednesday, February 12th. One analyst has rated the stock with a sell rating, fifteen have assigned a hold rating and two have given a buy rating to the company's stock. According to data from MarketBeat.com, the stock has a consensus rating of "Hold" and an average target price of $8.87.

Sage Therapeutics Profile

Sage Therapeutics, Inc, a biopharmaceutical company, develops and commercializes brain health medicines. Its product candidates include ZULRESSO, a CIV injection for the treatment of postpartum depression (PPD) in adults; and ZURZUVAE, a neuroactive steroid, a positive allosteric modulator of GABAA receptors, targeting both synaptic and extrasynaptic GABAA receptors, for the treatment of postpartum depression.